Boston Pharmaceuticals

1:45 PM - 2:00 PM (JST), Wednesday, March 6, 2019 ・ 2nd Floor
Boston Pharma is a translational drug development company. It was founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D Executive from Eli Lilly. With $600M committed capital from Gurnet Point Capital, Boston Pharma’s business model is focused on partnering and developing therapeutics from late pre-clinical to clinical POC. In the past 3 years, we have built an experienced clinical development team and acquired a diverse portfolio of fifteen programs in oncology, autoimmune, cardiovascular, dermatology, anti-infective, gastrointestinal, and metabolic, including recent deals with GSK, Novartis, and other Pharma and biotech partners. In principle, we are agnostic with regards to indication or molecular modality. During this conference, we are seeking in licensing and out licensing partnering discussions.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
BOS-589 / RETi
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided